Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Biology

Biochemistry

Medicine

Cancer Oncology

Internal Medicine

Show all topics

DOI

10.1016/s1470-2045(15)00038-8

Other Formats

PDF